RecruitingPHASE1, PHASE2NCT03213002

Oral Capecitabine and Temozolomide (CAPTEM) for Newly Diagnosed GBM

Studying Glioblastoma

Last synced from ClinicalTrials.gov

Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Northwell Health
Principal Investigator
John Boockvar, MD
Lenox Hill Hospital-Northwell Health
Intervention
Capecitabine(drug)
Enrollment
67 enrolled
Eligibility
18-74 years · All sexes
Timeline
20172027

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT03213002 on ClinicalTrials.gov

Other trials for Glioblastoma

Additional recruiting or active studies for the same condition.

See all trials for Glioblastoma

← Back to all trials